Education
About Us
Working with TipRanks
Follow Us
Lineage Cell Therapeutics, Inc. (LCTX)
:LCTX
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.04Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 10, 2025
|% Change Since: -7.55%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive advancements in the OpRegen program and manufacturing capabilities, alongside financial challenges and ongoing development hurdles in the OPC1 program. The progress in partnerships and potential additional funding weigh positively, but the financial losses and program challenges balance the sentiment.Company Guidance
During the fourth quarter and full year 2024 conference call for Lineage Cell Therapeutics, CEO Brian Culley provided updates on the company's key programs and financial outlook. The focus was on OpRegen, their leading candidate for dry AMD with geographic atrophy, which is in a Phase 2a study called the GAlette Study. Culley noted the study's progress and highlighted Roche and Genentech's ongoing commitment, including obtaining RMAT designation and continuing site openings. He also discussed the scalability of their GMP manufacturing process, emphasizing its importance for allogeneic cell therapies, and mentioned the OPC1 program for spinal cord injuries, which is undergoing enhancements in delivery and manufacturing processes. CFO Jill Howe reported a cash position of $47.8 million as of December 31, 2024, with a financial runway into Q1 2027, and discussed the potential for $36 million in additional funding linked to OpRegen clinical milestones. For the fourth quarter, Lineage reported total revenues of $2.9 million, operating expenses of $7.8 million, and a net loss of $3.3 million or $0.02 per share.OpRegen Program Progress
The OpRegen program, a cell transplant for dry AMD, is progressing well with the GAlette Study managed by partners Roche and Genentech. The study has been enrolling for nearly two years, and recent actions by Roche indicate a positive direction. Additionally, a three-year clinical update from the Phase 1/2a trial shows that the benefits have persisted.
Manufacturing Advancements
Lineage has been investing in scalable cell therapy manufacturing, aiming to deliver millions of doses. This effort has generated new intellectual property and achieved specific milestones, differentiating Lineage's capabilities in the cell therapy field.
Financial Strength and Strategy
Lineage reported cash, cash equivalents, and marketable securities of $47.8 million as of December 31, 2024, with an extended runway into Q1 2027. The company's financing strategy includes a milestone warrant that could access an additional $36 million, contingent on clinical success.
---
LCTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LCTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 10, 2025 | $0.53 | $0.53 | 0.00% |
| Nov 14, 2024 | $0.88 | $0.86 | -2.27% |
| Aug 08, 2024 | $0.88 | $0.90 | +2.27% |
| May 09, 2024 | $1.18 | $1.17 | -0.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Lineage Cell Therapeutics, Inc. (LCTX) report earnings?
Lineage Cell Therapeutics, Inc. (LCTX) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Lineage Cell Therapeutics, Inc. (LCTX) earnings time?
Lineage Cell Therapeutics, Inc. (LCTX) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LCTX EPS forecast?
LCTX EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---